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Hepcidin is a critical inhibitor of iron export from
macrophages, enterocytes, and hepatocytes. Given that it is
filtered and degraded by the kidney, its elevated levels in
renal failure have been suggested to play a role in the
disordered iron metabolism of uremia, including
erythropoietin resistance. Here, we used a novel
radioimmunoassay for hepcidin-25, the active form of the
hormone, to measure its levels in renal disease. There was a
significant diurnal variation of hepcidin and a strong
correlation to ferritin levels in normal volunteers. In 44
patients with mild to moderate kidney disease, hepcidin
levels were significantly elevated, positively correlated with
ferritin but inversely correlated with the estimated
glomerular filtration rate. In 94 stable hemodialysis patients,
hepcidin levels were also significantly elevated, but this did
not correlate with interleukin-6 levels, suggesting that
increased hepcidin was not due to a general inflammatory
state. Elevated hepcidin was associated with anemia, but,
intriguingly, the erythropoietin dose was negatively
correlated with hepcidin, suggesting that erythropoietin
suppresses hepcidin levels. This was confirmed in 7 patients
when hepcidin levels significantly decreased after initiation
of erythropoietin treatment. Our results show that hepcidin is
elevated in renal disease and suggest that higher hepcidin
levels do not predict increased erythropoietin requirements.
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Replacement of erythropoietin (EPO) is the mainstay of
treatment of anemia in renal failure, reflecting the impor-
tance of renally produced EPO in regulating hematocrit.
However, it is now recognized that sensitivity to EPO therapy
in end-stage renal disease is often limited by a functional
defect in iron availability, and in most patients intravenous
iron therapy improves the response.1 Resistance to EPO has
been associated with increased mortality in renal disease,2
and there are concerns that regular intravenous iron
administration may have adverse consequences.3,4 It is
therefore hoped that a better understanding of abnormal
iron homeostasis in renal disease would permit therapeutic
improvements increasing EPO responsiveness.
Hepcidin is the key hormone governing mammalian iron
homeostasis. It is produced predominantly in the liver and
undergoes furin-mediated cleavage to produce the 25-amino-
acid active form (hepcidin-25).5 Hepcidin causes degradation
of the iron export protein ferroportin, which is expressed by
macrophages, enterocytes, and hepatocytes, thereby prevent-
ing iron export from these cells into the plasma.6 Hepcidin is
regulated by iron intake7 and anemia,8 and its deficiency
underlies hereditary hemochromatosis in humans9 and
causes iron overload in mouse models.10
N-terminal cleavage of hepcidin-25 produces the biologi-
cally less active hepcidin-22 and hepcidin-20 peptides11,12
that, together with hepcidin-25, are excreted in the urine.12,13
Recent work has suggested that hepcidin-25, like
b2-microglobulin, is freely filtered and reabsorbed in the
proximal tubule.14 In this context, it has been suggested that
the functional iron deficit that accompanies renal disease may
be attributable to increased circulating levels of hepcidin due
to impaired urinary excretion.15
Hepcidin expression is also induced by inflammatory
stimuli such as interleukin-6 (IL-6),16 and because the
erythropoietic demand for iron is large in relation to the
quantity normally available in the plasma,12,17 it is believed
that excess hepcidin in inflammatory states reduces the iron
recycling that is necessary for erythropoiesis, leading to the
anemia of chronic disease, which is characterized by reduced
erythropoiesis and reduced serum iron despite apparently
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normal stores.18,19 These features are similar to EPO
resistance in kidney patients,20,21 and an important hypoth-
esis is that increased hepcidin causes, and could be a marker
of, EPO resistance.
To date, measurement of hepcidin in humans has proved
difficult—previous studies measured circulating prohepcidin,
levels of which do not appear to be physiologically relevant,22
or urinary hepcidin using a semiquantitative dot-blot assay.23
More recently, accurate mass spectrometry-based techniques
have been developed.24 We have developed a specific
immunoassay for plasma hepcidin, and report measurement
of circulating hepcidin in a large group of renal patients and
healthy controls.
RESULTS
Plasma hepcidin levels in 64 healthy controls (34 men)
showed a log-normal distribution, with median 10.8 ng/ml
and normal range 2–55 ng/ml (5th–95th percentiles). As
predicted, log hepcidin was strongly correlated with log
ferritin (R¼ 0.673, Po0.0001). Hepcidin levels were higher
in men, although this difference was entirely accounted for by
the variation in ferritin.
Because iron and EPO levels show a diurnal variation in
normal people,25 we measured levels in eight healthy male
controls consuming their usual diet over a 24 h period
(Figure 1a). This suggested a diurnal pattern with peak levels
in the afternoon, although a flattened profile was observed in
the two subjects with lowest ferritin levels (28 and 33 ng/ml,
respectively, others 470 ng/ml). These results were con-
firmed by analysis of paired samples in a further group of 18
controls (8 men; Figure 1b), in whom plasma hepcidin at
1600 hours was approximately twice the level at 0800 hours
(mean ratio 2.17, P¼ 0.0001).
We next examined the effect of reduced renal clearance by
measuring plasma hepcidin in 44 patients with chronic
kidney disease not requiring dialysis (CKD group; age 24–92),
and 94 stable hemodialysis patients (HD group; age 28–87;
Figure 2). The CKD group had varying degrees of renal
impairment (estimated glomerular filtration rate (eGFR)
8–98 ml/min), and none were receiving EPO or intravenous
iron therapy, which were administered to the HD group,
aimed at maintaining hemoglobin 411 g/100 ml and ferritin
4400 ng/ml. Hepcidin was log-normally distributed in both
groups: the CKD group exhibited elevated levels compared to
controls, with median 26.5 ng/ml (5th–95th percentiles:
3.1–153 ng/ml, Po0.001); and the HD group had signifi-
cantly higher levels, with median 58.5 ng/ml (5th–95th
percentiles: 27.6–158 ng/ml, Po0.001). Moreover, hepcidin
was inversely correlated with eGFR in the CKD group
(R¼0.530, P¼ 0.0002).
To confirm that the elevated measurements in renal
disease were not purely due to the accumulation of
degradation products, we performed the assay on pooled
plasma from control and HD patients, separated by high-
performance liquid chromatography (HPLC; Figure 3).
Although a small additional peak was detected in HD
plasma, over 90% of the signal corresponded chromatogra-
phically to hepcidin-25.
We next investigated diurnal variation of hepcidin in CKD
and HD patients, and hepcidin clearance during dialysis.
Morning (0800 hours) and afternoon (1600 hours) levels
were measured in four CKD patients (eGFR 12–28) and six
HD patients on a non-dialysis day (Figure 1b), showing no
clear diurnal pattern (65.5 vs 65.5 ng/ml in CKD group and
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Figure 1 | Diurnal profiles of plasma hepcidin. (a) Diurnal profile
of plasma hepcidin in eight healthy controls, with group mean
(bold line). (b) Morning and afternoon comparisons in a further 18
controls showing a substantial rise in the afternoon (P¼ 0.0001).
In four chronic kidney disease (CKD) patients and six hemodialysis
(HD) patients (on a non-dialysis day) this diurnal variation in
hepcidin was not observed.
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Figure 2 | Plasma hepcidin levels in healthy controls, patients
with chronic kidney disease (CKD), and hemodialysis patients
(HD). CKD group is shown as a scatterplot with linear regression
(P¼ 0.0002). Group medians are significantly different at 10.8,
26.5, and 58.5 ng/ml (Po0.001 for control vs CKD, and Po0.0001
for CKD vs HD).
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58.3 vs 57.8 ng/ml in HD group). Pre- and post-dialysis
samples were also taken from six patients, showing no
reduction following a standard dialysis session (68.7 vs
69.7 ng/ml for pre- and post-dialysis, respectively).
The relationship between hepcidin and ferritin was
preserved in CKD patients (R¼ 0.845, Po0.0001;
Figure 4a) and by multivariate regression, ferritin was a
stronger predictor than eGFR, although significant correla-
tions remained for eGFR after correction for ferritin
(b¼0.230, P¼ 0.017) as well as for ferritin after correction
for eGFR (b¼ 0.745, Po0.001). In the HD group, this
relationship with ferritin was no longer observed, possibly
because there was less variation in levels, which were high due
to target-driven treatment with intravenous iron (Figure 4a).
To confirm that hepcidin responds to iron status despite renal
failure, samples were taken from four iron-naive CKD
patients before and after administration of a first dose of
intravenous iron. Hepcidin levels in these patients increased
from 18.1±9.6 to 59.3±18.6 ng/ml at 24 h after infusion
(P¼ 0.047; Figure 4b).
To examine whether elevated plasma hepcidin may be
partly attributable to inflammatory signals, we measured
C-reactive protein and IL-6, and identified no correlation
with hepcidin in CKD (R¼ 0.20, P¼ 0.19 for C-reactive
protein and R¼ 0.28, P¼ 0.07 for IL-6) or HD patients
(R¼ 0.04, P¼ 0.69 for C-reactive protein and R¼ 0.12,
P¼ 0.26 for IL-6).
It has been hypothesized that elevated hepcidin may
explain reduced sensitivity to EPO in dialysis patients.26,27 To
investigate this, we compared hepcidin level, hemoglobin,
and EPO dose in dialysis patients (Figure 5a). High hepcidin
levels were associated, as expected, with low hemoglobin
(b¼0.290, P¼ 0.004), but contrary to the hypothesis, were
also strongly and independently related to low EPO dose
(b¼0.335, P¼ 0.001), regardless of whether EPO dose was
measured as an absolute value, or normalized by body weight
or by hemoglobin. This correlation was consistent across each
tertile of hemoglobin (Figure 5b). The relationship between
hepcidin and other clinical parameters in this group is shown
in Tables 1 and 2.
To confirm the suspicion that EPO therapy may be
responsible for reducing hepcidin, we measured levels in
seven CKD patients as they were starting EPO (20 mg
darbepoietin alfa weekly) for the first time (Figure 6). Plasma
hepcidin fell from 70.0±4.7 to 60.7±6.0 ng/ml during the
first few days (P¼ 0.045) and remained at similar levels when
patients were retested after 2–4 weeks of continued therapy.
A potential mechanism by which hepcidin might be
reduced by EPO involves growth differentiation factor 15
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Figure 3 | Elution profile of hepcidin immunoreactivity
following high-performance liquid chromatography
separation of pooled control and hemodialysis plasma. As
expected, a single peak due to hepcidin-25 is present in control
plasma. In hemodialysis plasma a small second peak is also
present, but over 90% of the immunoreactivity is
chromatographically identical to hepcidin-25.
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Figure 4 | Relationship between iron status and plasma
hepcidin. (a) Correlation between log hepcidin and log ferritin in
healthy controls (solid line, R¼ 0.673, Po0.0001), patients with
chronic kidney disease (CKD, dotted line, R¼ 0.845, Po0.0001 for
univariate, b¼ 0.745, Po0.001 for model including eGFR), and
hemodialysis patients (HD). The correlation is lost in the HD group
due to high ferritin levels associated with intravenous iron
treatment. The relationship between ferritin and hepcidin is
similar in CKD and control groups. (b) In CKD patients receiving
intravenous iron for the first time, hepcidin rises promptly after
infusion of 200 mg iron sucrose (P¼ 0.047). All samples were
taken at 1500 hours.
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(GDF15), which may function as a signal from active bone
marrow to suppress hepcidin expression.28 We found that in
the HD group, plasma GDF15 was significantly correlated
with EPO dose (R¼ 0.205, P¼ 0.047), consistent with its role
as a marker of marrow activity, but there was no correlation
between plasma GDF15 concentrations and hepcidin levels
(R¼0.002, P¼ 0.98). However, GDF15 levels were posi-
tively correlated with hepcidin levels in the CKD group
(R¼ 0.593, P¼ 0.002). Together, these results suggest that
altered hepcidin levels in renal disease are not due to changes
in circulating GDF15.
DISCUSSION
These data confirm, using a novel assay, previous observa-
tions that hepcidin levels rise during the day and are elevated
in renal impairment,29,30 providing a possible mechanism for
the impaired iron absorption observed in renal disease.1 Our
findings also demonstrate a number of important additional
points. First, the normal diurnal variation in hepcidin is
suppressed in those with reduced levels due to low iron
stores, or elevated levels due to severe renal impairment.
Second, even in the presence of moderate renal impair-
ment, hepcidin remains closely related to iron stores, and
responsive to changes in iron status, without any obvious
relationship to the inflammatory mediators measured.
Third, although high hepcidin is associated with low
hemoglobin, consistent with its role in restricting erythropoi-
esis, it is also strongly and independently associated with low
EPO dosage. Rather than reflecting hepcidin’s influence on
EPO requirement, and potential as a marker of EPO resistance,
these data are consistent with a model in which hepcidin levels
are directly or indirectly suppressed by EPO. This concept is
supported by the reduction in hepcidin seen in CKD patients
starting EPO therapy. Such an effect on hepcidin expression is
also suggested by animal experiments in which stimulation of
erythropoiesis by venesection or EPO administration is
sufficient to suppress hepcidin mRNA levels.8,31
In conclusion, we have shown that a raised plasma
hepcidin level, with flattening of the normal diurnal
variation, occurs in kidney disease. This increase in hepcidin
level reflects both the degree of renal impairment and iron
storage, but is independent of variation in markers of
inflammation. The results also suggest that EPO therapy can
suppress hepcidin, ameliorating disordered iron transport as
well as treating EPO deficiency.
Table 1 | Continuous clinical parameters in the hemodialysis
group
Mean
5th
percentile
95th
percentile b P
Age 64.6 39.2 83.0 0.082 0.414
Ferritin* (ng/ml) 550 291 1014 0.247 0.013
Body mass index
(kg/m2)
25.2 19.3 32.1 0.085 0.397
Albumin (g/l) 34.4 28.0 41.0 0.101 0.319
Cholesterol (mmol/l) 3.55 2.40 5.20 0.236 0.018
Creatinine (mmol/l) 669 405 886 0.133 0.178
spKt/V 1.81 1.47 2.13 0.051 0.632
C-reactive protein*
(mg/l)
12.9 2.8 31.2 0.016 0.874
Interleukin-6* (pg/ml) 5.2 1.2 12.8 0.195 0.054
GDF15 (ng/ml) 4.25 2.27 7.28 0.072 0.467
spKt/V, hemodialysis dose; GDF15, growth differentiation factor 15.
Distributions of clinical parameters in the hemodialysis group, and correlation with
hepcidin in a model adjusted for erythropoietin and hemoglobin. (*skewed variables
that were normalized by log transformation for regression analysis).
Table 2 | Gender and comorbidity in the hemodialysis group
% Hepcidin ratio P
Sex (male) 66.0 0.74 0.079
Residual renal function 37.9 1.09 0.739
Diabetes 36.6 1.16 0.375
Vascular disease 52.1 1.23 0.217
Ratio of plasma hepcidin levels measured in men vs women, and in the presence vs
absence of significant residual renal function and comorbid conditions.
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Figure 5 | Relationship between erythropoietin dose and
plasma hepcidin in dialysis patients. (a) Inverse correlation
between log hepcidin and erythropoietin (EPO) dose in dialysis
patients (R¼0.301, P¼ 0.003 for univariate, b¼0.335,
P¼ 0.001 for model including hemoglobin). Dashed lines show
90% CI for linear regression. (b) Plasma hepcidin by tertiles of EPO
dose and hemoglobin (HB), showing that the association of higher
EPO dose with lower hepcidin is conserved across hemoglobin
concentrations and that, within each EPO dose tertile, lower
hemoglobin is associated with higher hepcidin.
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MATERIALS AND METHODS
This study was approved by the local NHS Research Ethics
Committee (06/Q0406/134) and all participants gave informed
consent according to the Declaration of Helsinki principles. Renal
patients were recruited from a regional center with mixed
ethnicity, mainly Caucasian and South Asian. All samples were
taken into heparinized tubes with immediate centrifugation and
frozen storage.
Hepcidin was measured by a novel competitive immunoassay:
polyclonal rabbit anti-hepcidin-25 antibody was produced by
immunization of a female New Zealand white rabbit with synthetic
hepcidin-25 (Bachem, UK) conjugated to Keyhole limpet hemocya-
nin. Binding was assessed by competition with I125-labeled hepcidin-
25, separated by secondary antibody (mean binding standard curve
is shown in Figure 7). The assay is linear up to 200 ng/ml, with a
detection limit of 0.6 ng/ml, intraassay precision 7.2% (3 ng/ml) and
5.8% (35 ng/ml), and interassay precision 7.6% (3 ng/ml) and 6.7%
(35 ng/ml). Analytical recovery was 98% (5 ng/ml) and 97% (40 ng/ml).
No cross-reactivity with human insulin, glucagon, angiotensinogen,
b-defensin 1–4 or a-defensin 1 proteins was observed. As expected,
some cross-reactivity with synthetic hepcidin-20 (Peptide Institute,
Osaka, Japan) was observed, but was only 9.6% (200 ng/ml). There
was no cross-reactivity with prohepcidin, as demonstrated by
measurement of hepcidin and prohepcidin immunoreactivity
(enzyme-linked assay from DRG International, NJ, USA) in
HPLC-fractionated control plasma (Figure S1).
High performance liquid chromatography (HPLC) was per-
formed on pooled control (n¼ 5) and HD (n¼ 5) plasma samples,
preextracted using C18 Sep-Pak Cartridge (recovery 480%).
Extracted HPLC analyzed 1 ml/min collected fractions using
Discovery BIO Wide Pore C18 Column with a 15:45% ACN:H2O
gradient for 70 min. Eluted fractions were then assayed using
hepcidin RIA for immunoreactive fragments.
IL-6 and GDF15 were measured by enzyme-linked assays (R&D
Systems, Abingdon, UK). Differences between groups were mea-
sured using Student’s t-test, and associations between parameters
were measured using Pearson’s correlation coefficient. Skewed
variables were log-transformed. SPSS 16.0 (SPSS Inc., Chicago, IL,
USA) was used for multivariate regression analysis using variables
significant in bivariate correlations.
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